Where can I find news about ORR?

Press releases, SEC filings, and prospectus updates from the fund issuer are listed on this page. Militia Long/Short Equity ETF (ORR) news is sourced from regulatory filings and the issuer's investor relations feed.

How can I track ORR's SEC filings?

ORR's 485APOS / 485BPOS prospectus filings, N-CSR shareholder reports, and other regulatory filings are listed on this page with direct links to the SEC EDGAR copies. Filings update as the issuer submits them, typically semi-annually for shareholder reports.

Where can I find ORR's prospectus?

Militia Long/Short Equity ETF (ORR)'s most recent prospectus is linked in the filings section on this page. Issuers publish the full prospectus on their product page and re-file it annually with material updates flagged in the 485BPOS amendment.

ORR

Militia Long/Short Equity ETF

NASDAQ·Asset Management · Financial Services

$38.92$0.22−0.56%

After hours·$38.92+0.00%

Market closed·Oct 27 4:00 PM EDT

News & Analysis

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S
Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the n
gurufocus.comOct 25, 2026 · 12:00 PM
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
RYBREVANT FASPROâ¢ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced he
gurufocus.comOct 25, 2026 · 10:00 AM
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecif
gurufocus.comOct 25, 2026 · 8:00 AM
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancerPR Newswire
gurufocus.comOct 25, 2026 · 4:00 AM
IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
IMDELLTRAÂ IN COMBINATION WITH IMFINZIÂ REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCERPR NewswireTHOUSAND
gurufocus.comOct 24, 2026 · 11:00 AM
Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026
Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026PR NewswireGUANGZHOU, C
gurufocus.comOct 24, 2026 · 8:00 AM
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
[url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated inve
gurufocus.comOct 24, 2026 · 5:00 AM
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRÎ±-targeting ADC at ESMO 2026PR NewswireINDI
gurufocus.comOct 24, 2026 · 3:00 AM

Fund Documents

SEC filings for ORR aren't indexed yet (common for recently launched funds). Browse the issuer's filings on SEC EDGAR directly.

Frequently Asked Questions About ORR

Where can I find news about ORR?: Press releases, SEC filings, and prospectus updates from the fund issuer are listed on this page. Militia Long/Short Equity ETF (ORR) news is sourced from regulatory filings and the issuer's investor relations feed.
How can I track ORR's SEC filings?: ORR's 485APOS / 485BPOS prospectus filings, N-CSR shareholder reports, and other regulatory filings are listed on this page with direct links to the SEC EDGAR copies. Filings update as the issuer submits them, typically semi-annually for shareholder reports.
Where can I find ORR's prospectus?: Militia Long/Short Equity ETF (ORR)'s most recent prospectus is linked in the filings section on this page. Issuers publish the full prospectus on their product page and re-file it annually with material updates flagged in the 485BPOS amendment.

Militia Long/Short Equity ETF

Frequently Asked Questions About ORR

Militia Long/Short Equity ETF

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

Frequently Asked Questions About ORR

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026